With the widespread recognition that T-cells are the key mediators of psoriasis, current treatment strategies have focused on reducing the population of these cells or modulating their activity through the use of immunosuppressive treatments such as methotrexate, cyclosporine, and psoralens plus ultraviolet A radiation. Now, a greater understanding of the immunologic basis of psoriasis based on scientific advances are enabling the development of rationally designed, biologic agents that selectively target specific elements in the immune system that are directly involved in the pathophysiology of psoriasis. This review discusses several basic strategies for biologic therapies for psoriasis and concludes that the allergist/immunologist is eminently qualified to treat this immune skin disorder.
Document Type: Research Article
Publication date: March 1, 2006
More about this publication?
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.